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Abstract
Central giant cell granuloma (CGCG) is an uncommon benign intraosseous lesion that 
occurs almost exclusively in the jaws that has variable clinical behavior and is diﬃ  cult to 
predict. The CGCG of the jaws is usually a non-neoplastic bone lesion accounting for 
fewer than 7% of all benign tumors of the jaws. Before the early 1950s, central giant cell 
lesions (GCLs) of the jaws were generally diagnosed as giant cell tumor (GCT) usually 
found in epiphyseal regions of long bones. Giant cell lesions (GCLs) are mandatorily 
diagnosed in consideration with clinical and radiological features which predicts its 
aggressive and non-aggressive behavior. The incidence in the general population is 
very low and patients are generally younger than 30 years. CGCG belongs together 
with GCT, brown tumor of hyperparathyroidism and cherubism to the so-called GCLs, 
which can be diﬃ  cult to distinguish solely by microscopic examination. GCT of the long 
bones is practically identical with CGCG of the jaws on histopathologic examination 
and is considered by some authors as a manifestation of the same disease, where age 
and local factors are responsible for diﬀ erent clinical characteristics. The aim of this 
review is to focus on general considerations of CGCG along with its management 
and to diﬀ erentiate between various centrally placed GCLs which mimic each other 
histologically and sometimes clinically.
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Introduction
Central giant cell granuloma (CGCG) is an uncommon locally 
destructive, but benign lesion that occurs in the craniofacial 
region especially in jaw bones.[1,2] There are only sporadic 
case reports with extragnathic skeleton involvement.[3] 
The incidence of CGCG is very low and is commonly seen 
in patients younger than 30 years. Before the early 1950s, 
central giant cell lesions (GCL) of the jaws were generally 
diagnosed as giant cell tumor (GCT) which was usually found 
in epiphyseal regions of long bones. Although its etiology and 
pathogenesis are unknown, its histology and clinical behavior 
has been studied in detail and are now well established 
thus diﬀ erentiating CGCG from other GCLs.[4] Recently, 
WHO has defi ned it as a localized benign but sometimes 
aggressive, osteolytic proliferation consisting of fi brous tissue 
with hemorrhage and hemosiderin deposits and presence of 
osteoclast-like giant cells with reactive bone formation.[5] 
Although originally termed as giant cell reparative granuloma, 
the clinical behavior of many of these lesions has been 
inconsistent with a reparative process, so the term “reparative” 
has been omitted today.[6] Clinically CGCG may behave 
variably ranging from asymptomatic slow growth to aggressive 
growth with pain, cortical perforation or root resorption. The 
treatment of choice for CGCG is local curettage. However, 
aggressive CGCG may recur which may necessitate extensive 
bone surgery resulting in defects in jaws.[7]
Discussion
CGCG is an intraosseous lesion consisting of cellular fi brous 
tissue that contains multiple foci of hemorrhage, aggregation of 
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multinucleated giant cells and occasionally trabeculae of woven 
bone.[8] This condition was considered to be malignant, when 
fi rst described 140 years back. Jaﬀ e et al. in 1940, considered it 
to be a true neoplastic GCT of the bone and in 1952 suggested 
the term giant cell reparative granuloma; however, at present it is 
considered as a GCL.[9]
Although, etiopathogenesis of CGCG of the jaw bones has 
not been clearly established; it has been suggested that it occurs 
as a result of an unusual exacerbated reparative process related 
to previous trauma and intraosseous hemorrhage which triggers 
the reactive granulomatous process.[7] According to Geschickter 
and Copeland the giant cells are derived from proliferating 
multinucleated cells associated with the resorption of deciduous 
tooth roots, from fusion of endothelial cells of capillaries, 
fi broblasts, or monocyte/macrophage lineage.[10] Although the 
multinucleated giant cells are prominently seen in CGCG or 
GCT, they are not considered as the primary proliferating tumor 
cells. It is hypothesized that the giant cells arise from peripheral 
blood mononuclear cells recruited by the spindle-shaped 
stromal cells, which stain positive immunohistochemically for 
the proliferation marker proliferative cell nuclear antigen and 
are considered as the proliferating tumor cells. In short, the 
giant-cells of CGCG are derived from a subset of mononuclear 
phagocytes. These mononuclear precursor cells diﬀ erentiate 
into mature giant-cells under the infl uence of receptor activator 
of nuclear factor κβ ligand (RANKL) -expressing, proliferating 
spindle-shaped (osteoblast-like) stromal cells. According to 
Sapp these cells are slightly modifi ed osteoclasts.[11]
Except for true neoplastic and dysplastically malformed giant 
cells, almost all other giant cells in cases of GCT, aneurysmal 
bone cyst and fi bro-histiocytic lesion are of macrophage 
lineage. With repetitive nuclear divisions unaccompanied by 
cytoplasmic division, multinucleated giant cells are formed. 
This process may require heightened telomerase activity and 
some gene rearrangement. Exposure to certain infectious agents 
and endogenous or exogenous foreign substances bring about 
several conformational and enzymatic changes in macrophages. 
Exogenous foreign bodies and released endogenous unexposed 
substances are frequent causes of giant cell transformation 
of macrophages. These include haemorrhages (red cells and 
plasma), cholesterol, keratin, hair, milk secretion, sperms and 
mucin, etc. The giant cells in giant cell tumor of bone appear to 
be transformed circulating monocytes, many if not all of which 
have converted into active osteoclasts.[12]
The peak incidence of CGCG is in the second decade and is 
more common in females.[13] It is frequently reported that lesions 
of CGCGs are located anterior to the mandibular fi rst molar and 
often cross the midline.[14] A recent review of 80 cases suggested 
that there is an equal predilection for the posterior mandible.[15] 
CGCGs can cause displacement of teeth and developing tooth 
germs, but rarely cause tooth resorption.
GCLs are usually unifocal. Multifocal lesions should alert 
the clinician to the possibility of hyperparathyroidism or if 
bilateral, cherubism or Noonan syndrome. GCLs are osteoclast-
rich tumors that are histopathologically indistinguishable from 
those seen in cherubism and Noonan syndrome. Nevertheless, 
patients with isolated GCLs do not have the cherubism related 
germ line SH3BP2 mutation and the lesions do not contain 
somatic SH3BP2 mutations. This fi nding suggests that even 
though all GCLs might appear the same histologically, they are 
likely to have a diﬀ erent etiopathogenesis.[16]
CGCG must be distinguished from cherubism, which is an 
autosomal dominant disorder with similar histologic fi ndings 
but diﬀ erent clinical and radiologic features. Cherubism is 
characterized by bilateral expansion of the mandible and/or the 
maxilla and becomes evident within the fi rst few years of life. It 
includes multifocal and multilocular cystic lesions of the jaws.[17] 
The microscopic features of CGCG and those of cherubism also 
share similarities with the brown tumors of hyperparathyroidism 
and aneurysmal bone cysts. They reveal non-neoplastic fi brous 
lesions containing round and spindle-shaped, mononuclear cells 
and embedded scattered multinucleated giant cells. Another 
entity of giant cell-rich granulomatous osseous lesions is the GCT 
of the bone. In contrast to the CGCG, the GCT is considered 
truly neoplastic.[18] Malignant transformation in CGCGs is 
a rare phenomenon. Malignancy in GCT of the bone was 
reported by Bertoni et al. in 1.8% of the cases described. These 
malignancies can be either primary or secondary, including giant 
cell-rich osteosarcomas, fi brosarcomas and malignant fi brous 
histiocytomas.[19]
Multiple concurrent CGCGs are reported to be associated 
with some form of the inherited syndrome or systemic disease. 
The possibility of any associated systemic condition, such as 
hyperparathyroidism, should be ruled out through special 
investigations like endocrinology and biochemical tests, X-ray 
pelvis, hand wrist radiograph and chest X-ray.
Usually, CGCG presents as a well-defi ned unilocular or 
multilocular radiolucent lesion.[13] Although CGCGs are 
considered as benign osseous lesions, some authors divides 
CGCG into two categories based on its clinical and radiographic 
features: (a) Non-aggressive lesions which are usually slow 
growing and asymptomatic and do not show cortical perforation 
or root resorption with less chances of recurrence, (b) aggressive 
lesions are usually seen in younger patients, are painful, grows 
rapidly, larger overall, often cause cortical perforation, root 
resorption and have a tendency to recur.[20]
CGCG presents with two major histological features fi rstly, 
a highly cellular fi broblastic stroma with plump spindle-shaped 
cells with high mitotic rate and high vascular density. Second, the 
prominent multinucleated giant cells throughout the fi broblastic 
stroma, distributed irregularly often located most numerously 
around areas of hemorrhage. The morphology of these giant-
cells varies from case to case. The cell size is variable, and the 
number of nuclei ranges from only a few to several dozen.[21]
As the cell of origin is unknown, and both aggressive and non-
aggressive CGCL appear same histologically, many authors have 
considered biomarkers as a means of diﬀ erentiating these lesions 
and correlating these with the clinical behavior and treatment 
outcome.[22,23]
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CGCG cannot be diﬀ erentially diagnosed from GCT without 
clinical and histological aids. CGCG generally occurs in younger 
subjects than GCT. Histologically, CGCG shows a patchy 
distribution of fewer giant cells with small sized nuclei which 
are less in number, and are surrounding the vascular channels 
with presence of plump bland fi broblasts and hemosiderin 
deposits. Whereas in GCT, giant cells are uniformly scattered, 
have a larger number of nuclei, and there is the absence of 
fi broblasts and hemorrhage, but with a background of polygonal 
mononuclear cells which is lacking in CGCG. Osteoid deposits 
may be occasionally seen in CGCG but not in GCT.[24]
Cherubism and Noonan’s syndrome also show similar 
histological features like CGCG but with diﬀ erent clinical and 
radiographic features. Cherubism is characterized by bilateral 
expansion of mandible or maxilla and becomes evident within 
fi rst few years of life. It includes multifocal and unilocular cystic 
lesions of the jaw.[17]
Role of Immunohistochemistry in Diagnosis
The angiogenic activity of GCLs was proposed as a determinant 
of the aggressive nature of GCLs. Vered et al. were unable to 
fi nd elevated vascular endothelial growth factor and fi broblast 
growth factor in these tumors and concluded that GCLs have 
low angiogenic activity.[25]
Dewsnup et al. studied the expression of cluster diﬀ erentiation 
(CD34), a cell-cell adhesion factor and cell-surface glycoprotein 
found in hematopoietic precursor and capillary endothelial 
cells. They determined that clinically aggressive GCTs have 
an increased vascular density compared with non-aggressive 
lesions based on CD34 staining. Furthermore, they suggested 
that CD34 evaluation can identify aggressive lesions amenable 
to anti-angiogenic therapy, even at the time of biopsy. These 
fi ndings strongly suggest that the CD34 staining density level has 
a high positive predictive value for biologic behavior and might 
help in planning treatment and predicting the outcome.[26]
Vered et al. immunohistochemically stained mononuclear 
giant cells for glucocorticoid and calcitonin receptors in an 
attempt to provide a reliable and practical tool for selecting an 
appropriate therapeutic agent to treat GCLs. They found that the 
mononuclear giant cells of GCLs stained for both glucocorticoid 
and calcitonin receptors.[27]
Flanagan et al. proposed intralesional corticosteroid for 
GCLs. Their reasoning was that multinucleated giant cells 
are osteoclasts and dexamethasone has been shown to inhibit 
osteoclast-like cells in marrow cultures. Giant cells in GCLs 
have also been shown to have calcitonin receptors. Calcitonin 
inhibits osteoclast/giant cell function and has been suggested as 
a treatment modality.[28]
The expression of Ki-67, a nuclear antigen expressed in all 
active phases of the cell cycle was similar in both aggressive 
and non-aggressive CGCG and therefore is not suitable for the 
diﬀ erentiation between aggressive and non-aggressive CGCGs. 
Regarding the neoplastic versus non-neoplastic nature of CGCG 
in the jaws, fi ndings indicate that a factor secreted by fi broblast/
osteoblast RANKL binds to stromal monocyte-derived cells to 
induce giant cell formation. The RANKL mechanism suggests 
that the giant cell component might be reactive. They also hinted 
at the possibility of fi broblasts/myofi broblasts in the CGCGs 
being lesional cells and giant cells being reactive cells.[29]
Immunohistochemistry has helped to establish the lineage of 
the cells in CGCG, but is of no value in assessing the aggressiveness 
of the lesion. However, calcitonin receptor expression is found to 
exhibit a statistically signifi cant diﬀ erence with more expression 
in the aggressive type of CGCG. Immunoreactive response to 
muramidase, α-1 antichymotrypsin, and α-1 antitrypsin support 
the theory that the multinucleated giant cells are derived from 
macrophages.[30]
Clinical and radiographic fi ndings dictate the management of 
CGCG. Well-defi ned localized lesions are treated with curettage 
and have shown a low rate of recurrence. Whereas for extensive 
multiple lesions a more radical excision is necessary. Carnoy’s 
solution is commonly used to limit the proliferation of tumor. 
Additionally the treatment with steroids or calcitonin may be 
used as adjunct to surgery.[31]
The rate of recurrence varies between 13 and 49%. Malignant 
transformation in CGCGs is a rare phenomenon.[19] Therefore, 
in our opinion, clinical parameters, especially the tumor size, are 
the most reliable indicator of prognosis.
Conclusion
Based on the review of the literature and our own observations, 
CGCG can be classifi ed as a reactive proliferative disease having 
typical histologic features, dynamic biologic characteristics and 
variable clinical patterns. Their site of origin, clinical, radiographic 
features along with routine histopathological staining are thought 
to indicate its diagnosis; however, the histogenesis of the 
tumor remains controversial. Despite the substantial progress 
in treatment modalities available in the present era, the wide 
spreading nature of this disease has a strong hold in determining 
the prognosis. For the improvement of diagnosis and therapy of 
CGCG, controlled studies based on standardized protocols on 
signifi cant population may help to enhance the knowledge about 
this rare bone disease.
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